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Abstract Patients with essential thrombocythemia (ET)
aged less than 60 years, who have not suffered a previous
vascular event (low-risk patients), may develop thrombotic
or hemorrhagic events. So far, it has not been possible to
identify useful markers capable of predicting which of
these patients are more likely to develop an event and
therefore who needs to be treated. In the present study, we
analysed the relationship between vascular complications
and longitudinal blood counts of 136 low-risk ET patients
taken over a sustained period of time (blood cells dyna-
mism). After a median follow-up of 60 months, 45 out of
136 patients (33 %) suffered 40 major thrombotic and 5
severe hemorrhagic complications. A total number of 5,781
blood counts were collected longitudinally. Thrombotic
and hemorrhagic events were studied together (primary
endpoint) but also separately (thrombotic alone = sec-
ondary endpoint; hemorrhagic alone = tertiary endpoint).
The primary endpoint showed no significant association
between platelet and WBC count at diagnosis and risk of
any event (platelet, p = 0.797; WBC, p = 0.178), while
Hb at baseline did show an association (p = 0.024). In the
dynamic analysis with Cox regression model, where the
blood count values were studied by time of follow-up, we
observed that the risk for Hb was 1.49 (95 % CI 1.13–1.97)
for every increase of 1 g/dL, and that this risk then mar-
ginally decreased during follow-up. WBC was associated
with an increased risk at baseline for every increase of
1 9 109/L (hazard ratio (HR) 1.07, 95 % CI 1.01–1.13,
p = 0.034), the risk was stable during follow-up (HR 0.95,
p = 0.187 at 60 months). Also, for each increment at
baseline of 100 9 109 platelets/L, HR was increased by
1.08 (95 % CI 0.97–1.22, p = 0.159) and decreases during
follow-up. In conclusion, this study is the first to evaluate
This work represents part of the thesis of Dr. Elisabeth Maria Blo¨chl,
which has been presented and recently approved as a MD diploma
thesis at the Department of Oncohaematology of Innsbruck Medicine
University, Austria (Professor Gu¨nther Gastl and Prof Michael
Steurer).
A. Piccin (&)  I. Pusceddu  A. Marabese  D. Corvetta 
S. Cortelazzo
Department of Haematology, San Maurizio Regional Hospital,
Bolzano, South Tyrol, Italy
e-mail: apiccin@gmail.com
A. Piccin  M. Steurer  E. M. Blo¨chl  G. Gastl
Division of Haematology & Oncology, University Hospital,
Innsbruck, Austria
M. Mitterer
Oncohaematology Unit, Meran Hospital, Merano,
South Tyrol, Italy
L. Marcheselli
Department of Diagnostic, Clinical and Public Health Medicine,
University of Modena and Reggio Emilia, Modena, Italy
I. Bertozzi  M. L. Randi
Department of Internal Medicine, University of Medicine,
Padua, Italy
E. Elli  E. M. Pogliani
Department of Haematology, University of Milano Bicocca,
Milan, Italy
D. Veneri  O. Perbellini  M. Krampera  G. Pizzolo
Department of Medicine, Section of Hematology,
University of Verona, Verona, Italy
E. Pacquola  M. Gottardi  F. Gherlinzoni
Department of Haematology, Ca` Foncello Hospital, Treviso,
Italy
123
Intern Emerg Med (2015) 10:451–460
DOI 10.1007/s11739-015-1186-8
in ET low-risk patients, the risk of developing a throm-
botic/hemorrhagic event considering blood counts over
time. Overall our study shows that the risk changes over
time. For example, the risk associated with WCC is not
linear as previously reported. An interesting new finding is
that PLT and even Hb contribute to the risk of developing
vascular events. Future treatments should take into con-
sideration these findings and aim to control all parameters
over time. We believe this early study may help develop a
dynamic analysis model to predict thrombosis in the single
patient. Further studies are now warranted to further vali-
date our findings.
Keywords Essential thrombocythemia  Low-risk 
Thrombosis  Hemorrhage
Introduction
Essential thrombocythemia (ET) is a clonal disorder
characterized by the abnormal proliferation of megakary-
ocytes followed by uncontrolled increase of circulating
platelets (PLT) [1]. Patients with ET have a relatively
benign prognosis [2], but thrombotic and hemorrhagic
events may indeed occur over time, leading to severe
morbidity [3–5]. Previous studies by Cortelazzo et al. [6–
8] showed that age[60 years and previous thrombotic or
hemorrhagic events are strongly associated with a higher
risk of developing further events. Conversely, the so-
called low-risk ET group (young patients without previous
vascular events), may also develop thrombotic or hemor-
rhagic events during follow-up. However, agreement is
lacking about the role of blood counts in this risk. A
relationship between high WBC ([11 9 109/L) and the
risk of thrombosis has been shown, [9, 10] but these
findings have been contradicted by other authors [11–13].
Recently, Passamonti et al. re-examined this issue using a
dynamic model based on two sequential evaluations of
WBC count within 2 years from diagnosis, and find that
patients with an increase greater than one-third of the
baseline WBC count, have a significantly higher risk of
developing thrombosis [14]. A correlation between ele-
vated WBC count during follow-up and risk of thrombosis
has also been reported by Campbell et al. [15], in high-
risk ET patients (PT-1 trial). These findings prompted us
to assess the role of blood cell values and the risk of
thrombotic and hemorrhagic events due to their changes
over time in a large group of low-risk ET patients, fol-
lowed up for a long period of observation. Moreover, we
also repeated our statistical analysis using the new IPSET
risk classification (low, intermediate and high).
Patients and methods
Patients
Patient data from 1981 to 2011 was retrospectively
obtained from nine Haematology Departments in Northern
Italy and the Department of Haematology at Innsbruck
University of Medicine in Austria. All patients were
enrolled in a consecutive manner at all centers, and were all
at first diagnosis. A database ad hoc was created and shared
between all centers. 130 patients had a diagnosis of low-
risk ET according to the 2008 WHO criteria (all cases had
bone marrow biopsy performed), primary myelofibrosis
was also excluded [16]. Another six cases were diagnosed
according to the PVSG criteria. All patient data was col-
lected anonymously. Approval for this multi-centre study
was obtained from the Ethics Committee of the leading
centre.
Patients undergoing treatment with hydroxyurea or
aspirin were excluded from this study.
Risk category
– WHO risk groups: low-risk patients were defined as
\60 years of age without prior thrombotic or hemor-
rhagic events [7], and a platelet count\1,500 9 109/L
with or without cardiovascular risk factors such as
diabetes, hypertension, hypercholesterolemia and
smoking or JAK-2 mutational status [16, 17].
– IPSET risk groups: we also performed a secondary
analysis with the updated IPSET criteria giving to each
patient a score as follows: Age [60 years (1 point),
history of thrombosis (2 points), presence of cardio-
vascular risk factors (diabetes, hypertension, smok-
ing = 1 point) and presence of the JAK2 V617F
mutation (2 points).
Using this model, we determined three thrombosis risk
groups: low risk for thrombosis (total score zero or 1),
intermediate risk (score 2) and high risk (score[ 2).
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Blood counts
Longitudinal blood counts, including white blood count
(WBC), platelet count and haemoglobin (Hb) concentra-
tion, were recorded from the date of diagnosis (entry time)
until the development of an event or up to 5 years of fol-
low-up (exit time).
Events
Events were defined as thrombotic events (stroke, transient
ischemic attack, myocardial infarction, peripheral artery
thrombosis, deep or splenic vein thrombosis and pulmon-
ary embolism), and hemorrhagic events. Moreover, hem-
orrhagic events requiring transfusion[2 units, or causing a
decrease in Hb to[2 g/dL were defined as major hemor-
rhagic events, while all others were defined as minor
hemorrhagic events.
End points
Because ET may cause either hemorrhagic or thrombotic
events, we considered the primary end point to be any
thrombotic or hemorrhagic event. Subsequently, we re-
analysed all data looking at thrombotic events only, this
represents the secondary endpoint of our study.
Data collection and statistical analysis
We defined as fixed covariates the variables recorded at
baseline only (entry time), and as varying covariates, the
consecutive blood counts recorded longitudinally during
5 years of follow-up, or until an event occurred (exit time)
[11]. Binary covariates were reported as a proportion, and
comparisons at baseline were made using v2 test, where
appropriate, or Fisher’s exact test. Continuous covariates
were expressed by means of median and interquartile range
(IQR), and compared with the Mann–Whitney test. The
association between blood counts recorded longitudinally
and time at blood sampling (in years), were analysed
according to a linear regression analysis, using a linear
regression with random factors (random effect). This was
necessary because consecutive blood count measurements
were taken on the same subject, similar to what was sug-
gested by recent studies [16]. In the linear mixed model,
the association between the time at sampling (in years), and
the blood count, was adjusted for age at control, and gen-
der. Furthermore, WBC and platelet counts were trans-
formed in logarithmic form [Log10] to allow a Gaussian
distribution. The event-free survival (EFS) of the primary
end points of arterial or venous thrombosis, or serious
haemorrhage, was defined from the date of diagnosis to the
date of an event, or the date of the last blood count
(censored cases). EFS of the primary endpoints cumulative
probability was estimated by means of the Kaplan–Meier
method [18, 19]. Comparison between curves of EFS of the
primary end points was performed using the log-rank test
[20]. If the curves crossed, we used the Renyi type test in
addition to the log-rank test [21].
To assess the effect of the blood count covariates, we
used the Cox proportional hazard model [22].
We fitted a Cox proportional hazards regression model,
stratified by type of event, following two approaches:
(i) using restricted cubic spline basis for the blood count
predictor, and (ii) using time-dependent covariates [23].
Blood count covariates were measured with the time of
follow-up (time scale months) in logarithmic form [ln_e
(1 ? month)]. All regression coefficients and hazard ratios
(HR) were reported together with their confidence interval
at 95 % (95 % CI) or standard error (SE). As this study was
a retrospective analysis, we did not calculate a sample size.
For all tests, a two-sided p value\ 0.05 was considered
significant, to demonstrate a moderate strength of evidence
against the null hypothesis. This level of probability is
helpful for providing clinically useful advice. All statistical
analysis was performed using the statistical package Stata
10.1 SE (College Station, TX 77845 USA).
Results
Patients
From 1981 to 2011, a total of 136 consecutive patients with
low-risk ET were diagnosed in ten cancer centres. 130 were
diagnosed according to the 2008 WHO criteria (bone
marrow biopsy performed), while another six cases were
diagnosed according to the PVSG criteria. Their demo-
graphic and baseline characteristics are reported in
Table 1. The median age was 49 years (range
18–59 years), and the M/F ratio was 0.50.
Blood counts
During a median follow-up of 60 months (range 1–360), a
total of 2,661 longitudinal blood counts of 136 low-risk ET
patients were analysed. Regarding the blood count at
diagnosis, the median value for Hb was 14.2 g/dL (range
11.7–17.9), WBC count was 8.2 9 109/L (range 4.4–24),
and the platelet count was 718 9 109/L (range 451–1,806).
Other risk factors
Other risk factors included: diabetes (n = 2/113, 2 %),
hypertension (n = 22/122; 18 %), hypercholesterolemia
(n = 16/91; 18 %), hypertriglyceridemia (n = 8/114;
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7 %), active smoker (n = 18/74; 24 %) and JAK2V617F
mutation (n = 63/106; 59 %). Also, 70 patients (81 %)
were in the IPSET low-risk group.
Vascular events and risk factors
After a median follow-up of 80 months (range 1–360
months), 45 out of 136 patients (33 %) had 40 thromboses
including: 3 strokes, 11 transient ischemic attacks, 12
myocardial infarctions, 2 peripheral arterial thromboses, 2
deep and 7 splanchnic vein thromboses, 2 pulmonary
embolisms, 1 acute coronary syndrome and 5 major hem-
orrhagic events (4 nasal bleeding and 1 gastrointestinal
bleeding). The median EFS of the primary end points was
204 months (95 % CI 164–240 months), and the overall
estimated risk of the primary end points at 5 and 10 years
was 14 % (95 % CI 9–24 %) and 30 % (95 % CI
20–45 %), respectively (Fig. 1). No statistical difference
was found between the estimated risk of arterial and venous
thrombosis at 5 and 10 years (p = 0.238) (data not shown).
Moreover, neither cardiovascular risk factors (hypertension,
p = 0.519; hypercholesterolemia, p = 0.149, hypertri-
glyceridemia, p = 0.915 and smoke, p = 0.123), nor JAK-
2 mutational status (p = 0.463, Renyi test), influenced the
rate of vascular complications. Regarding blood counts, we
did not find a significant association between platelet and
WBC count at diagnosis and thrombotic/hemorrhagic
events (platelet, p = 0.797; WBC, p = 0.178) or throm-
bosis (platelet, p = 0.850 and WBC, p = 0.256). Instead,
Hb at baseline showed an association with thrombosis/
hemorrhage (p = 0.024) and thrombosis (p = 0.006).
Adopting the newly established IPSET criteria, there
were 70 patients with low risk and 66 patients with inter-
mediate risk, however, IPSET did not show an association
with thrombotic/hemorrhagic events (p = 0.656) or
thrombosis only (p = 400).
Table 1 Patient characteristics
Variable N Median (range)
Age, years 136 49 (18–59)
Hemoglobin, g/dL 136 14.2 (11.7–17.9)
WBC 109/L 136 8.2 (4.4–23.8)
Platelets 109/L 136 718 (451–1,806)
N n (%)
Gender, male 135 45 (33)
JAK2 V617F mutation 106 63 (59)
Smokers 74 18 (24)
Hypercholesterolemia 91 16 (18)
Diabetes 113 2 (2)
Hypertension 122 22 (18)
Hypertriglyceridemia 114 8 (7)
IPSET Score: low (0–1) 136 70 (51)
Risk: defined according to IPSET score (Barbui et al., Blood, 2012)
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Fig. 1 Cumulative event free
survival (EFS, median
204 months) of our low risk ET
patients with both thrombotic/
hemorrhagic events (a). Figure
b shows the EFS separated for
hemorrhagic (n = 5) and
thrombotic events. No statistical
difference was is found between
the estimated risk of arterial and
venous thrombosis at 5 years
(c). Figure d shows cumulative
distribution of venous and
arterial events
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Risk of developing a thrombotic or hemorrhagic event
A total number of 2,661 blood counts were collected
longitudinally in the 136 low-risk patients, with a median
time of 1.7 months (range 0.5–7) between each blood
sampling. Overall, during the follow-up time, after
adjusting for age and gender, Hb values decreased from
baseline in a linear manner (-0.11 g/dL by year,
p\ 0.001). The WBC and platelet counts showed a
similar trend over follow-up time (-0.09 9 109/L every
year, p = 0.058 and -26 9 109/L every year, p\ 0.001),
as reported in Fig. 2.
Risk analysis for the primary endpoint (all events)
The cumulative analysis of the relationship between blood
count values, modeled by means of restricted cubic spline
regression, and vascular thrombotic/hemorrhagic events,
evaluated with Cox proportional hazards regression mod-
els, shows that the risk increases when platelets are above
1,500–2,000 9 109/L (p = 0.012), while WBC and Hb do
not show an association with vascular events (p = 0.800
and p = 0.194, respectively) (Fig. 3a–c). From the
dynamic analysis with the Cox regression model, where the
blood count values were interacted by time of follow-up
(Table 2), we observe: (1) the risk of developing a vascular
event at baseline for Hb increases is 1.49 (95 % CI
1.13–1.97) for every increase of 1 g/dL, and this risk then
marginally decreases during follow-up (HR at 60 months
for any increase of 1 g/dL of Hb is 0.81 (95 % CI
0.65–1.03, p = 0.083); (2) WBC increases are associated
with an increased risk at baseline (HR 1.07, 95 % CI
1.01–1.13, p = 0.034) for every increase of 1 9 109/L, the
risk is stable during follow-up (HR 0.95, p = 0.187 at
60 months); (3) when platelet values and HR were con-
sidered, for each increment at baseline of 100 9 109
platelets/L, HR is increased by 1.08 (95 % CI 0.97–1.22,
p = 0.159), and tend to decrease during follow-up
(HR = 0.90, 95 % CI 0.81–1.01, p = 0.075 at 60 months)
(Fig. 3c–e).
Risk analysis for the secondary endpoint (thrombotic
events only)
Cox proportional hazards regression models, confirm an
increased risk of thrombosis when platelets counts are
above 1,500–1,700 9 109/L (p = 0.022) (Fig. 4a–c).
According to the model with the time-depending covariates
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Fig. 2 Shown blood cells dynamism in low risk ET patients with a thrombotic/haemorragic event. Hb hemoglobin g/dL, WBC white blood cells
9109/L in logarithm base 10 and platelets 9109/L in logarithm base 10
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(Table 3), the analysis confirms an association between Hb
and WBC and the risk of developing a thrombotic event at
baseline (HR = 1.64, p = 0.001 and HR = 1.08,
p = 0.010, respectively). The risk of thrombosis is reduced
during the follow-up for Hb (by any increase of Hb of 1 g/
dL at 60 months, HR = 0.78, 95 % CI 0.61–0.99,
p = 0.048) (Fig. 4c–e).
Risk analysis for the tertiary endpoint (hemorrhagic
events only)
The results of the tertiary endpoint (hemorrhagic events
only) analysis show an increased risk of haemorrhage
related to the increasing of WBC up to 13000 9 109/L
(p = 0.004). Conversely, a linear decreasing risk of
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Fig. 3 Primary endpoint risk analysis cumulative thrombotic/hemor-
raghic events. Shown cumulative dynamic hazard risk (HR) valuated
with Cox proportional hazards regression models by restricted cubic
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haemorrhage is seen with a decrease of the platelet count
(P = 0.031).
Analysis adopting the newly published IPSET criteria
Adopting the newly established IPSET criteria, low-risk
patients were 73 in number, while those with intermediate-
risk were 63. Interestingly, when either thrombotic or
hemorrhagic events are considered, Hb and WBC at
diagnosis show a statistically significant correlation with
the risk of developing an event (respectively, HR 1.49,
p = 0.005; HR 1.08, p = 0.034). However, because the
number of hemorrhagic events was small (n = 5), we
repeated the study looking only at the thrombotic events,
and in this case only WBC at diagnosis correlates with the
probability of developing an event (HR 1.08, p = 0.010).
Overall the trend between the low-risk patients identified
by the WHO criteria is similar to the trend of the low-risk
group identified with the IPSET criteria.
Discussion
Low-risk ET patients may develop thrombotic and hem-
orrhagic events, which carry severe morbidity and mor-
tality risks. For these reasons, we aimed to identify
predictors of thrombotic and hemorrhagic events. The
uniqueness of our study was to run a dynamic analysis with
a Cox regression model, where the blood count values were
studied by time of follow-up.
The estimate of thrombosis-free survival at 5 years is
superior in our study compared with the high-risk group, 85
versus 72 %, respectively. The rate of hemostatic
complications in our study cannot be directly compared
with other studies because of the wide range of reported
vascular events (ranging from 7.6 to 25 %) [12, 14, 24].
This discrepancy between different study findings may be
related to the use of different selection criteria, which
allowed the inclusion of subgroups, which represented
higher risk categories, such as those with early/prefibrotic
myelofibrosis [24], cardiovascular risk factors or JAK2
mutation. In fact, the newly proposed International Prog-
nostic Score of thrombosis in ET (IPSET-thrombosis)
includes only 48 % of young and asymptomatic patients in
the new low-risk group, while the remaining 52 % are
included in the intermediate-risk group or in a small frac-
tion of the high-risk group (5 %), thus confirming the
heterogeneity of the previously defined low-risk category
of ET patients [25].
Our findings are also in keeping with previous reports
showing that arterial and venous thrombosis are prevalent,
as only 4 % of patients suffered a major hemorrhage [12,
24]. In our study, the analysis of possible risk factors for
vascular events examined at diagnosis reveals that neither
blood count, nor cardiovascular risk factors nor JAK2
mutations are predictive for thrombosis or hemorrhage
during follow-up. Carobbio et al. suggest an association
between leukocytosis at diagnosis and thrombosis [10].
However, other studies do not show that platelet or leu-
kocyte counts at presentation are predictive of subsequent
vascular events [12, 14]. In contrast with the observations
of a recent study [26], but in keeping with the findings of
an earlier study on a similar population [12], multivariate
analysis excludes an association between either cardio-
vascular risk factors or JAK2 mutation and subsequent
vascular events.
Table 2 Cumulative Dynamic Cox regression model for thrombosis/hemorrhagic events (n = 136, n = 45 events)
Univariate analysis Coef. SE P HR 95 % CI
Gender, male 0.429 0.320 0.179 1.54 0.82–2.88
Prior treatment -0.348 0.352 0.324 0.71 0.35–1.41
Age/10 0.050 0.117 0.665 1.05 0.84–1.32
Risk group interim. vs low 0.142 0.300 0.637 1.15 0.64–2.08
(Hb-14) at diagnosis 0.398 0.142 0.005 1.49 1.13–1.97*
(Hb-14) 9 ln(months ? 1) -0.050 0.029 0.083 0.81 0.65–1.03**
(WBC-8.0) at diagnosis 0.063 0.030 0.034 1.07 1.01–1.13*
WBC 9 ln(month ? 1) -0.012 0.009 0.187 0.95 0.88–1.02**
(Plt-700)/100 at diagnosis 0.081 0.057 0.159 1.08 0.97–1.22*
(Plt-700)/100 9 ln(month ? 1) -0.024 0.014 0.075 0.90 0.81–1.01**
Hb hemoglobin g/dL, WBC white blood cell count 109/L, PLT platelet count 109/L, ln natural logarithm (basis e); e = 2.71828… Euler constant
* For every increase of 1 g/dL in hemoglobin or 1 9 109/L in WBC or 100 9 109/L in Plt at time of follow-up equal to zero
** For every increase of 1 g/dL in Hb or 1 9 109/L in WBC or 100 9 109/L in Plt at 60 months follow-up
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The results of the cumulative analysis conducted on
combined thrombotic and hemorrhagic events (primary
endpoint), explain at least in part, how cell dynamism
contributes to vascular events in ET. Previous studies have
always considered thrombotic and hemorrhagic events
independently.
Recent findings on ET pathophysiology suggest that not
only blood cell variations, but also qualitative blood cells
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Fig. 4 Secondary endpoint risk analysis: Thrombotic events only.
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alterations, contribute to events. For this reason, we believe
that thrombosis and hemorrhage are only the epiphenom-
enon of these changes, and we evaluated all events together
(primary endpoint), as well as independently for throm-
bosis only (secondary endpoint), or for haemorrhage only
(tertiary endpoint).
This primary endpoint analysis shows that a higher
WBC clearly increases the risk of cardiovascular events,
and similarly for PLT counts, (for each increment of PLT
of 100 9 109 platelets/L, HR was increased by 1.08
p = 0.159). However, this risk is reduced over time.
The secondary endpoint analysis (thrombotic events
only), shows that neither WBC nor PLT increases sig-
nificantly affect the risk of thrombosis. Another finding of
the secondary endpoint analysis, is that the risk of
developing a thrombotic event increases by 34 % (95 %
CI 7–69 %), for each increase of 1 g/dL of Hb after
60 months of follow-up. These results contradict previous
reports by Campbell et al. [15], who find a linear rela-
tionship between WBC count increases during follow-up
and risk of thrombosis. However, Campbell’s study did
not consider a model with the time-depending covariates,
using only a cubic spines one. Also, the maximum follow-
up was for only 60 days, while in our study it was for
60 months. Moreover, the discrepancies between the
Campbell study and our study might be due to the dif-
ferent inter-study population. In fact, our series included
only low-risk untreated ET patients, while the patients
considered in the Cambpell study were those from the PT-
1 study that were high-risk patients, who underwent cy-
toreduction. The finding of an association between Hb
increase and thrombosis has also been reported by Gan-
gant N in low-risk ET patients [12]. This further suggests
that the findings from the Campbell study are not valid for
low-risk ET patients. We do not have a clear explanation
for this finding, however, patients with ET often have a
high HCT and Hb levels, as ET and polycythemia vera
may overlap. However, information on patient hematocrit
was lacking.
The results of the tertiary endpoint analysis (hemor-
rhagic events only), shows that an increased risk of
haemorrhage is related to the increasing of the WBC levels,
while a linear decreasing risk of haemorrhage is seen with
decreasing platelet counts. However, we feel that these
finding should be considered with caution because of the
low number of hemorrhagic events.
Overall our study shows that the risk of developing any
hemorragic or thrombotic events changes over time. Thus,
the risk associated with WCC increases is not linear as
previously reported. The interesting new finding is that
PLT and even Hb somehow contribute to the risk of
developing any vascular event. At the present, we cannot
explain these findings, and moreover, we cannot explain
why risk of thrombosis or haemorrhage changes over time.
We can speculate that some patients may be developing
myelofibrosis (MF), and that these changes over time may
simply reflect the developing of a new disease phenotype
(moving from ET towards MF). Moreover, the slight risk
reduction seen over time with high PLT counts may be
attributed to a certain degree of Acquired von Willebrand
disease (avWD), which might balance the overall risk of
thrombosis, without being strong enough to induce haem-
orrhage. Future treatments should take into consideration
these findings, and aim to a control of blood parameters
over time. We believe this early study may help develop a
dynamic analysis model to predict thrombosis in any single
patient. Further studies are now warranted to validate our
findings.
Table 3 Cumulative Dynamic Cox regression model for only thrombosis events (n = 136, n = 40 thrombosis)
Univariate analysis Coef. SE P HR 95 % CI
Gender, male 0.521 0.337 0.122 1.68 0.87–3.26
Prior treatment -0.513 0.363 0.157 0.60 0.29–1.22
Age/10 0.070 0.124 0.576 1.07 0.84–1.37
Risk group interim. vs low 0.178 0.318 0.576 1.19 0.64–2.23
(Hb-14) at diagnosis 0.493 0.148 0.001 1.64 1.22–2.19*
(Hb-14) 9 ln(1 ? months) -0.060 0.030 0.048 0.78 0.61–0.99**
(WBC-8.0) at diagnosis 0.078 0.030 0.010 1.08 1.02–1.15*
WBC 9 ln(1 ? month) -0.020 0.010 0.060 0.92 0.85–1.00**
(Plt-700)/100 at diagnosis 0.042 0.065 0.517 1.04 0.92–1.18*
(Plt-700)/100 9 ln(1 ? month) -0.018 0.015 0.242 0.93 0.82–1.05**
Hb hemoglobin g/dL, WBC white blood cell count 109/L, PLT platelet count 109/L, ln natural logarithm (basis e); e = 2.71828… Euler constant
* For every increase of 1 g/dL in hemoglobin or 1 9 109/L in WBC or 100 9 109/L in Plt at time of follow-up equal to zero
** For every increase of 1 g/dL in Hb or 1 9 109/L in WBC or 100 9 109/L in Plt at 60 months follow-up
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